¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º OK.-]()!  
.1 Vu-@  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ jXtLo,km  
W!y)Ho  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) 48;~bVr}  
|fx#KNPf]  
1. ICAM-1 yTP[,bM  
y. T ct.  
2. interleukin 12(IL-12) UUD\bWfn  
[O [FCn  
3. tumor infiltrating lymphocyte !\3 }R25  
1 iquHn  
4. TCR/CD3 complex cj`#Tg.  
r,QJG$ Jo  
5. hematopoietin receptor family  Pb*q;9  
38<~R  
6. individual idiotype(IdI) %}\ vW  
{jrZ?e-q  
7. integrin "^18&>^  
x_]",2 W'  
8. colony-stimulatory factor (CSF) A>H*`{}  
S.qk%NTTD  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© fMgcK$  
^ yY{o/6  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? ;L#L Dk{Za  
XB6N[E  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ XCKY xv&  
h4J{jh.  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ"cIGNTLFA  
kyp U&F  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ c _R)P,P  
#nxER   
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) bjU 2UcI"<  
a15,'v$O  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ !"Z."fm*  
>DSNKU+j  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) Ak<IHp^Q  
48R]\B<R{  
3. immunoglobulin superfamily (IgSF) d=Rk\F'^J  
qk"oFP6  
4. selectin BH.:_Qrbh[  
9n06n$F  
5. anti-idiotypic antibody (¦ÁId) n"K {uj))  
hfl%r9o  
6. major histocompatibility complex(MHC) B}l}Aq8  
CuV=C Ay>  
7. immunotolerance <lg"M;&Ht  
muqfSF  
8. biological reponse modifier(BRM)  tH<9  
PVQ#>_~5  
9. immune reponse gene (Ir gene) 0+VncL)u  
U|y;b+n`  
10. reshaped antibody (or reconstituted antibody) GlV-}5W  
-.+KCt G$+  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© N9>'/jgZX  
q;Ar&VrlNq  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ @xW"rX#7f  
K~fDv  i  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? ~L4*b *W  
r(?'Yy  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ h M1&A  
/64^5DjTh  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? %BKR }  
#qiGOpTF.  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ (c*7VO;  
|GVGny<  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? qMW%$L\HA  
.SKNIct M  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Ilt L@]e  
c}I8!*\  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ 4Q`=t &u  
0x9F*i_  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? C.9eXa1wkT  
rz%[o,s  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ kgbr+Yw2X  
1X!f!0=g+  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: -$]DO5fY  
Ivl^,{4  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: MTFVnoZMQ_  
xjn8)C  
ÃâÒßѧ V~uA(3\U  
V[M$o  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© j5VRv$P  
@)ju P- o%  
1. CD8 39a]B`y  
Rp%\`'+Xz  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) @!O&b%8X%  
*a0I  Z  
3. immunoglobulin fold(Ig fold) j}?ZsnqV  
B+q+)O+  
4. cadherin (Ca-dependent cell adhesion moleculers) (+Nmio  
a ~iEps  
5. idiotype-anti-idiotypic antibody immune network theory )}9}"jrDlx  
F>_lp,G   
6. HLA class II antigen s:Ql](/B#  
[\%t<aa  
7. complementarity-determining region (CDR) ZWe$(?  
{arjW3~M:  
8. perforin(or pore-forming protein ,PFP) %?G.lej,x  
YrcC"  
9. high affinity IL-2 receptor yar IR|  
cZK?kz_Y  
10. artificial active immunization $6?KH7lA  
/s0VyUV=  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© &i}cC4i   
`3s-%>  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ2iINQK$  
owVUL~  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 V@xnz)^t  
F^v{Jqc  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ |2]WA'q  
o;-! ?uJ  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ v__Go kj-  
(#Kvm  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ ~,4Znuin  
?#y<^oNM  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? {7szo`U2  
C xN@g'  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 2Yf;b9-k  
 2x J5  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ TKydOw@P"  
!8M'ms>s=  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ {8Nd-WJ{  
z4UQ:z@  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ~PvzUT-^  
,Yt&PE  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© QI{Y@xQ  
71ybZ 0  
1. immunoglobulin gene rearrangement %),O9*[9  
Mo=-P2)>lt  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) 6$.Xj\zl  
iR=aYT~  
3. flow cytometry(FCM) N4NH)x  
W5;sps  
4. carrier effect )ciHY6  
_n gMC]-T  
5. positive selection of T lymphocytes in thymus ?P]md9$(+e  
|B.d7@{mM  
6. mouse TH1(Th1) and TH2(Th2) subsets ^ } L$[P  
)g F9D1eA  
7. perforin (pore-forming protein ,PFP) =Z$6+^L  
2p ,6=8^v  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) l<6/ADuS  
%syBm  
9. SH-2(src-homology region 2) m %3Kq%?O  
1 j8,Zrg1  
10. Ab2¦Â (internal image)  S_6 ;e|  
4v .6 _ebL  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© vX%gcs/@  
eL!6}y}W  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? (*]Y< ve  
mqw.v$>  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ?  UW3F)  
KS_d5NvYl  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠVGIc|Q=F  
Az[z} r4  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ ".4^?d_^VF  
Ek0.r)Nw  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠuy~j$lrn  
E{J;-+t  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) fM{Vy])J  
tA.C"  
ÃâÒßѧרҵ£º G y2XjO8b  
M\3!elp2z  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ 8iRQPV-"_  
Pc<ZfO #  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? }$ der  
"cx" d:  
´«È¾²¡Ñ§×¨Òµ£º z,WrLZC  
_DQdo  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ |Z;Av%%  
\JchcQ  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ,bJx| K  
RA}PM?D/  
Ïû»¯×¨Òµ£º 5:wf"3%%  
]@EjKgs  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ cP,jC(<N  
`{%*DHa  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 4p]Y`];U  
5"+* c@L  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ 2B# \683  
8eNGPuoL)  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© [0 $Y@ek[  
v|e>zm <  
1. Fas(CD95)/FasL Ua4} dW[w  
8cHZBM7'  
2. common chain of cytokine receptor Y:wds=lA  
LxbVRw  
3 . TCR/CD3 complex j>U.(K  
*UTk. :G5  
4. negaive selection of thymocytes :?,& u,8  
tU(6%zvR  
5. artificial active immune uo0(W3Q *  
2b<0g@~X  
6. anti-idiotypic uzS57 O%  
eu~ ;G H  
7. IgSF Cs$g]&a  
 GRNH!:e  
8. Integrin ?lTQjw{  
:F_U^pyG  
9. chemokine It4F;Ah  
x@/ !H<y  
10. B7/CD28 SXhJz=h  
U_:/>8})d  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© %c&h:7);  
%T&kK2d;  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ bv+PbK]iO  
[P<oyd@#  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£  ;HW@ZI  
'RPe5 vB  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 0_ ;-QAd  
R8mL|Vb|  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ i6[Hu 8  
H#f FU  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ f\ Qi()  
OH&&d=~  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ s8R.?mhH=  
m~2PpO  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1>n@`M8}  
?8`b  
1. B7/CD28 5Ba eHzI  
%/4ChKf!VR  
2. Th1 subset At"@`1n_u'  
qg|SBQ?6  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© aK 'BC>uFI  
_/hWzj=q  
4. antibody affinity maturation Fvg>>HVu  
<"6 }C)G  
5. AP-1 6m?}oMz  
QO~!S_FRH  
6. single chain variable fragment£¨ScFv£© >Ka}v:E  
y4+Km*am,W  
7. NK cell receptor usU5q>1  
nzU^G)  
8. Zinkernagel-Doherty phenomenon Nv w'[?m  
Z!DGCw  
9. Ig fold I~|.Re9a  
'V/+v#V+>  
10. CD40/CD40L U8 '}(  
8a)lrIg  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© HZKqGkE  
CKCot  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ w6aq/m"'  
OF-$*  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 8(]*J8/wt  
0.!_k )tu  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ *d b,N'rK  
},+ &y^  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ j"1#n? 0  
jnho *,X  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ HHzAmHt  
@Jr:+|v3B  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ SJ8Ax_9{q  
8#L V oR  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ *3 8 u ~n  
_Oc5g5_{  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© %?2y2O ,;  
0i[v,eS  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© >\[/e{Q"  
JCFiKt9n  
1.Co-stimulators (or co-stimulating molecules) (P'{A>aHl0  
8n??/VDRl  
2.NK-kB h>k[  
Nux   
3.Immunoglobulin superfamily s k_TKN`+  
=hY9lxW  
4.antigen-presenting cell (APC) zCji]:  
@k+ K_gR  
5.death domain #fy3 i+  
|tN:o= 6  
6.CCR and CXCR Q%r KKOX8  
pF/s5z  
7.Lectin (or mitogen) 2 :oAS  
%\^VxM  
8.Clusters of differentiation, CD) CFXr=.yz  
56o(gCj?y  
9.B7 family "*< )pnJ  
G ,e!!J  
10.Cytotoxic T lymphocyte, CTL) X4eoE  
 SwE bVwB  
11.IL-15 and IL-15 receptor (IL-15R) m`BE{%  
[>D5(O  
12.MHC restriction BEtFFi6ot  
&yRR!1n)H  
13.Affinity-chromatography TXT!Ae  
i^@hn>s$  
14.Cyctosprin A, CsA `*WzHDv5p  
@4G{L8Q}  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 4s9q Q8?  
KwNOB _  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© & LhQr-g  
Q[Gs%/>  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 1}R\L"  
3t W}a`z9  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 3aw-fuuIb  
-H F1c  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ Th X6e  
5,|of{8  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 4C[kj  
Z.`0  
ÃâÒßѧרҵ£º xb2j |KY7  
e=+q*]>  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ .qLX jU  
=gC% =  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ /[5\T2GI   
BoXPX2:  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ Yyw9IYB;  
.pG`/[*a  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) sf O{.#5<  
x \I uM  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) *x_e] /}  
V@ +X4`T  
1. ADCC(antibody dependent cell-mediated cytotoxicity) e5D\m g)  
_q4Yq'dI  
2. »·æß¾úËØ(cyclosporin) hY/qMK5  
9VMk?   
3. KIR(killer cell inhibitory receptor) 9rIv-& 7'm  
_$/Bt?h  
4. HLDA(human leucocyte differentiation antigen) ]x66/O\0u  
%!DTq`F  
5. Interleukin 18(IL-18) q;#bFPh  
'J)9#  
6. ÕûºÏËØ(integrin) m {&lU@uL  
_bRgr  
7. Fas/FasL Z{gDE o)  
GPx+]Jw8\  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) I+`>e*:@W  
[ {HTGz@(  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) iVo-z#  
%TO&  
10. Th1/Th2 v?}rA%so  
0b<Qs88yd>  
11. »ùÒòÒßÃç(DNAÒßÃç) >p`i6_P0P/  
:2+z_+k}<  
12. chemokines and chemokine receptor ^5)=) xVF  
8Pva]Q  
13. ÃâÒßÄÍÊÜ hu7o J H  
] .Ra=^q  
14. ¹²´Ì¼¤·Ö×Ó i>C%[dk9  
9 Z"WV5o  
15. ËÀÍö½á¹¹Óò(death domain) , zdK%V}  
e.Q'l/g  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) y-S23B(  
I]42R;Sc  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? n0t+xvNDF_  
i[wnG)  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠI0;gTpt9  
N/1xc1$SB  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î V2:S 9vO'  
 Y=H_U$  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ ks,d4b=->  
R*lq.7   
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå A;e"_$yt8  
I]cZcx,<q  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ _` Y%Y6O1/  
k4!p))ql  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) T hVq5  
LG{50sP`  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ .&Sjazk0XO  
BQv*8Hg B6  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ Fr<tk^~/  
'b6qEU#  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»